10
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Treatment of Patients with Clinical T3 Prostate Cancer

, , &
Pages 28-33 | Published online: 09 Jul 2009

  • Boyle P, Maisonneuve P, Napalkov P. Incidence of prostate cancer will double by the year 2030: the argument for. Eur Urol 1996; 29 (suppl 2): 3-9.
  • Sandblom G, Mattsson E, Nilsson J, Damber JE, Johansson JE, Lundgren R, et al. Prostate cancer registration in four Swedish regions 1996--differences in incidence, age structure and management. Scand J Urol Nephrol 1999; 33: 306-11.
  • Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-speci? c antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 270: 57-60.
  • Wolff JM, Zimny M, Burchers H, Wildberger J, Buell U, Jakse G. Is prostate-speci? c antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998; 33: 376-81.
  • Harrison SH, Seale-Hawkins C, Schum CW, Dunn JK, Scardino PT. Correlation between side of palpable tumor and side of pelvic lymph node metastasis in clinically localized prostate cancer. Cancer 1992; 69: 750-4.
  • Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993; 41: 113-20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.